These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31215546)

  • 21. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
    Chen MJ; Chou JC; Hsu WM; Liu JH
    J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of brimonidine tartrate on ocular hemodynamic measurements.
    Lachkar Y; Migdal C; Dhanjil S
    Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
    Toris CB; Camras CB; Yablonski ME
    Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of topical brimonidine on visual field in glaucoma.
    Ruiz Lapuente C; Ruiz Lapuente A; Link B
    Eur J Ophthalmol; 2001; 11 Suppl 2():S67-71. PubMed ID: 11592534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of alpha-2 agonists in neuroprotection.
    Wheeler L; WoldeMussie E; Lai R
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S47-51. PubMed ID: 12852434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
    Ma YR; Lee BH; Yang KJ; Park YG
    Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 36. Side-effect profile of brimonidine tartrate in children.
    Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
    Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
    Barnebey HS; Robin AL; Zimmerman TJ; Morrison JC; Hersh SB; Lewis RA; Coleman AL; Cinotti DJ; Walt J; Chen KS
    Ophthalmology; 1993 Jul; 100(7):1083-8. PubMed ID: 8100625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 0.2% brimonidine on retinal blood flow.
    Yu M; Li Y; Liu X; Ling Y; Zheng X
    Yan Ke Xue Bao; 2001 Mar; 17(1):42-5. PubMed ID: 12567595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
    Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
    Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.